🇺🇸 FDA
Patent

US 6162432

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

expired A61KA61K2039/505A61K38/00

Quick answer

US patent 6162432 (Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Dec 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Dec 19 2000 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
55
CPC classes
A61K, A61K2039/505, A61K38/00